23.02.2022 | Letter to the Editor
Integrin β5 and β7 expression in lenalidomide-resistant multiple myeloma cells
verfasst von:
Yutaka Hattori, Takumi Futo, Ryo Uozaki, Daiju Ichikawa, Takashi Yamaguchi, Tomofumi Yamamoto, Maiko Matsushita, Maki Hirao
Erschienen in:
International Journal of Hematology
|
Ausgabe 4/2022
Einloggen, um Zugang zu erhalten
Excerpt
Recently, Hosen N et al. reported frequent expression of activated integrin β7 in multiple myeloma (MM) patients though the clinical significance was not known [
1]. They are also conducting a clinical trial using CAR-T-cell therapy targeting activated integrin β7 [
1,
2]. Here we report association of expression of integrin β5 and/or β7 with lenalidomide resistance. …